Back to top

Analyst Blog

XenoPort, Inc. (XNPT - Snapshot Report) and Astellas Pharma Inc. recently announced the launch of Regnite extended-release tablets in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).

The Japanese Ministry of Health, Labor and Welfare approved the drug in January 2012. In its press release, the company stated that there are around 2.1 million people with RLS in Japan.

We note that in December 2005, XenoPort had entered into a licensing agreement with Astellas for the exclusive rights to develop and commercialize Regnite in Japan, Korea, the Philippines, Indonesia, Thailand and Taiwan.

XenoPort has received $65 million to date under the collaboration agreement and is entitled to receive additional milestone payments of $20 million. The company is also eligible to receive royalties on a percentage basis on net sales of Regnite in the Astellas territory.

In addition, XenoPort and GlaxoSmithKline plc (GSK - Analyst Report) co-develop and co-promote the drug in the US under the trade name of Horizant. Recently, it was approved by the US Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN) in adults.

Horizant is already approved in the US for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults. However, the product is not recommended for use in patients who are required to sleep during the day and remain awake at night. Glaxo recorded approximately $1.3 million in Horizant sales in the first quarter of 2012.

Our Recommendation

We currently have a Neutral recommendation on XenoPort. The stocks carry a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%